碳酸氢钠治疗对CKD患者代谢性酸中毒血管内皮功能的影响:一项初步随机交叉研究
这项初步、前瞻性、开放标签的14周交叉研究,纳入20例eGFR 15-44 ml/min/1.73 m²且血清碳酸氢盐16-21 mEq/L的CKD患者,比较口服碳酸氢钠与对照对血管内皮功能的影响。主要终点为肱动脉血流介导的舒张(FMD)变化。结果显示碳酸氢钠治疗显著改善FMD,组间差异为1.8%(95%CI 0.3-3.3,P=0.02)。
要点
- 碳酸氢钠治疗使血清碳酸氢盐显著升高(+2.7±2.9 mEq/L,P≤0.001)。
- 碳酸氢钠组FMD从4.1%±4.1%升至5.2%±2.9%(P=0.04),对照组无显著变化。
- 治疗组血清磷和完整FGF23显著升高,骨标志物和钙化倾向无显著变化。
核心结论
- 在3b期和4期CKD合并代谢性酸中毒患者中,碳酸氢钠治疗显著改善血管内皮功能。
研究设计与样本
- 初步、前瞻性、开放标签14周交叉研究,纳入20例eGFR 15-44 ml/min/1.73 m²且血清碳酸氢盐16-21 mEq/L的CKD患者。
- 每周期6周,期间洗脱2周,治疗目标为血清碳酸氢盐≥23 mEq/L。
主要发现
- 碳酸氢钠组血清碳酸氢盐显著升高(+2.7±2.9 mEq/L,P≤0.001),对照组无变化。
- 碳酸氢钠组FMD从基线4.1%±4.1%升至6周时5.2%±2.9%(P=0.04),对照组从4.6%±3.1%变为4.1%±3.4%(P=0.20)。
- 与对照相比,碳酸氢钠治疗使FMD显著增加(均值1.8%;95%CI 0.3-3.3;P=0.02)。
- 治疗期间血清磷和完整成纤维细胞生长因子23显著升高,骨标志物和血清钙化倾向无显著变化。
临床怎么用
- 对于3b-4期CKD合并代谢性酸中毒(血清碳酸氢盐16-21 mEq/L)患者,可考虑口服碳酸氢钠纠正酸中毒以改善血管内皮功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: We examined the effect of alkali replacement for metabolic acidosis on vascular endothelial function in patients with CKD. METHODS: We performed a pilot, prospective, open-label 14-week crossover study examining the effect of oral sodium bicarbonate treatment on vascular function in 20 patients with an eGFR of 15-44 ml/min per 1.73 m2 with low serum bicarbonate levels (16-21 mEq/L). Each period was 6 weeks in duration with a 2-week washout period in between. Patients were treated to goal serum bicarbonate of ≥23 mEq/L. The primary end point was change in brachial artery flow-mediated dilation (FMD) between treatment and control conditions. Secondary end points included changes in markers of inflammation, bone turnover, mineral metabolism, and calcification. RESULTS: Eighteen patients completed the study and were included in the primary efficacy analysis. The mean (SD) age and eGFR were 59 (12) years and 26 (8) ml/min per 1.73 m2, respectively. Serum bicarbonate increased significantly with sodium bicarbonate treatment (+2.7±2.9 mEq/L, P≤0.001), whereas there was no change in bicarbonate levels in the control group. FMD significantly improved after sodium bicarbonate therapy (mean±SD, FMD baseline: 4.1%±4.1%; 6 weeks: 5.2%±2.9%; P=0.04) There was no significant change in FMD in the control group (mean±SD, FMD baseline: 4.6%±3.1%; 6 weeks: 4.1%±3.4%; P=0.20). Compared with control, sodium bicarbonate treatment resulted in a significant increase in FMD (mean, 1.8%; 95% confidence interval, 0.3 to 3.3; P=0.02). There was no significant change in bone markers or serum calcification propensity with treatment. Serum phosphorus and intact fibroblast growth factor 23 increased significantly during treatment. CONCLUSIONS: Treatment of metabolic acidosis with sodium bicarbonate significantly improved vascular endothelial function in patients with stages 3b and 4 CKD.
引用
- Kendrick J, Shah P, Andrews E, et al. Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study. Clin J Am Soc Nephrol. 2018. PMID: 30237219. doi:10.2215/CJN.00380118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。